| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc.
The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics' v1.1 RaDaR test. Natera is evaluating its options, including an appeal and further enforcement with other patents.
Importantly, these patents are distinct from U.S. Patent No. 11,519,035 (the ‘035 patent), and yesterday's decision has no impact on the validity or enforceability of the ‘035 patent. The ‘035 patent was the basis for a preliminary and then permanent injunction entered against NeoGenomics, which removed its RaDaR v1.0 product from the market.
Posted In: NTRA
